Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

European Archives of Psychiatry and Clinical Neuroscience

Volumn 267, Issue 2, 2017, Pages 173-176

  Hashimoto, Kenji ^a   Kakiuchi, Takeharu ^b   Ohba, Hiroyuki ^b   Nishiyama, Shingo ^b   Tsukada, Hideo ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Dopamine D2 3 receptor; Esketamine; Monkey; R ketamine; Release

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ESKETAMINE; KETAMINE; R KETAMINE; RACLOPRIDE C 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RHESUS MONKEY; SINGLE DRUG DOSE; ANIMAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; METABOLISM; NEOSTRIATUM; PROCEDURES;

ANIMALS; ANTIDEPRESSIVE AGENTS; KETAMINE; MACACA MULATTA; MALE; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84964321130     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-016-0692-7     Document Type: Article

References (18)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
2. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802
3. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864
4. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939–946
5. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172:950–956
6. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684
7. Zhang JC, Li SX, Hashimoto K (2014) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141
8. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632
9. Hashimoto K (2015) The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72–73
10. 2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover? Positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci 20:7067–7073
11. Yamamoto S, Ohba H, Nishiyama S, Harada N, Kakiuchi T, Tsukada H, Domino EF (2013) Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. Neuropsychopharmacology 38:2666–2674
12. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, Mori S, Yamashita T (1997) A high resolution animal PET scanner using compact PS-PET detectors. IEEE Trans Nucl Sci 44:1277–1282
13. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539
14. Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231:2041–2042
15. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. doi:10.1016/j.biopsych.2015.10.018
16. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38
17. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35–43
18. 3 receptor antagonist ondansetron on the ketamine-and dizocilpine-induced place preferences ion mice. Eur J Pharmacol 385:99–102